• IV Workflow Management Systems Keep Pace With Expanding Ambulatory Infusion Market

    IV Workflow Management Systems Keep Pace  With Expanding Ambulatory Infusion Market
    By Gina ShawIV workflow management systems (IVWMS) have long been a fixture of inpatient sterile compounding, and their footprint is expanding rapidly. Health systems are now pushing these platforms into ambulatory infusion centers, 503B outsourcing facilities, and home infusion pharmacies, each of which carries its own safety demands, regulatory requirements, and operational constraints.“This is encouraging,” said Mark Neuenschwander, the founding director of the THRIV Coalition for IV Accu
  • The Value Case for Outpatient ID Pharmacy

    By Gina ShawTodd Sorensen, PharmDWhen Todd Sorensen, PharmD, asked a room of infectious disease pharmacists at the newly combined Making a Difference in Infectious Diseases and Society of Infectious Disease Pharmacists 2026 meeting, in Orlando, Florida, how many were actively billing fee-for-service for their cognitive work, not a single hand went up. The same question in the previous session had yielded the same answer: none.Dr. Sorensen, the senior executive associate dean for strategic initia
  • ACHC Opens Simulated Cleanroom Suite for Hands-on Sterile Compounding Training

    ACHC Opens Simulated Cleanroom Suite for Hands-on Sterile Compounding Training
    By Gina ShawThe Accreditation Commission for Health Care (ACHC) has opened a fully functioning simulated cleanroom suite at its new headquarters in Cary, North Carolina, giving pharmacists and pharmacy technicians a place to practice and validate sterile compounding technique under USP General Chapter <797> and <800> conditions in a near-identical environment to a working pharmacy, without interrupting operations or creating any potential patient care issues.The facility, managed by
  • PN Use Survey Finds Continued Room for Improvement

    PN Use Survey Finds Continued Room for Improvement
    By Karen BlumThe 2025 ASPEN Parenteral Nutrition (PN) Use Survey identified several encouraging trends, including a major shift toward multidisciplinary care, along with a few areas of concern, such as lagging use of standardized order forms that boost patient safety and macronutrient regimens that fall short of treatment guidelines.The quantitative cross-sectional survey of 1,160 clinicians was designed to address multiple steps in the PN use process and updates previous surveys from 2011 and 2
  • Advertisement

  • Expert Strategies for Surviving IVWMS Downtimes

    Expert Strategies for Surviving IVWMS Downtimes
    By Gina ShawWhen an IV workflow management system (IVWMS) goes down, staff accustomed to relying on it must switch to manual procedures, often under pressure. Those skills can fade without practice, two sterile compounding experts told attendees at NHIA26, in Denver.“Training staff in manual processes is essential, and you need redundancy in place wherever possible, especially for equipment such as ACDs [automated compounding devices] and compounding pumps,” said Glen Gard, CPhT-Adv, CSPT, a
  • First mRNA Flu Vaccine Puts Pharmacists on Counseling Front Line

    First mRNA Flu Vaccine Puts Pharmacists on Counseling Front Line
    By Fran KritzThe FDA’s approval of the first mRNA influenza vaccine, Moderna’s mRNA-1010 (mFlusiva), is likely to prompt questions from patients and clinicians, and pharmacists should be prepared to answer them.Moderna said it plans to deliver supplies “to select retailers” in time for the 2026-2027 flu season, which typically begins in October.“When there’s a new vaccine, people are often unsure about whether it works and what their experience will be,” said Brigid Groves, PharmD,
  • AI Helpful in Patient Care, but Always Check Its Outputs

    AI Helpful in Patient Care, but Always Check Its Outputs
    By Karen BlumArtificial intelligence can help with several administrative and clinical tasks in patient care, but clinicians are still needed to review, vet, and build on the responses generated by AI tools, speakers said during the ASPEN 2026 Nutrition Science & Practice Conference, in Long Beach, California.Summaries, Drafting, and DocumentationOn the administrative side, AI tools can be used to review and summarize emails and help draft responses, or to sort emails into categories and fla
  • FDA Compounding Panel Backs 6 of 7 Peptides Despite Safety Risks in Oversight and Production

    FDA Compounding Panel Backs 6 of 7 Peptides Despite Safety Risks in Oversight and Production
    By Gina Shaw Rita Jew, PharmDThe FDA Pharmacy Compounding Advisory Committee’s (PCAC’s) recommendation that six of seven peptides be added to the 503A bulk drug substances list has alarmed leading medication safety experts.The move departs from the evidence-based process the agency normally follows and leaves several unresolved safety questions in place, noted Rita Jew, PharmD, the president of the Institute for Safe Medication Practices (ISMP), part of ECRI. Demand for peptide produ
  • Advertisement

  • FDA Approves Zilucoplan Once-Daily Autoinjector for Generalized Myasthenia Gravis

    FDA Approves Zilucoplan Once-Daily Autoinjector for Generalized Myasthenia Gravis
    By PPN StaffThe FDA has approved zilucoplan (Zilbrysq, UCB) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody–positive.Zilucoplan is the first self-administered, once-daily autoinjector administration option for this form of gMG. The autoinjector is designed to automatically deliver a predetermined dose when activated against the skin to ease the self-administration process.“For a chronic condition like gMG, having differe
  • Does a Designated Pharmacist Improve OPAT Outcomes?

    Does a Designated Pharmacist Improve OPAT Outcomes?
    By Meaghan Lee Callaghan and Landon GrayDoes including a designated pharmacist in managing outpatient parenteral antimicrobial therapy (OPAT) improve patient outcomes?A new study presented at MAD-ID x SIDP 2026 suggests yes, but more research is needed.Study authors Meg Parmalee, PharmD, a PGY-2 oncology pharmacy resident, and Tamanna Talwar, PharmD, a PGY-1 ambulatory pharmacy resident, both at UNC Health, in Chapel Hill, North Carolina, spoke with Infectious Disease Special Edition at the conf
  • AXS26 Panel: Keep Cybersecurity Top of Mind

    AXS26 Panel: Keep Cybersecurity Top of Mind
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksRansomware attacks that prevent e-prescribing and firewall breaches that provide a direct line to protected health information are among cybersecurity risks pharmacists face daily, whether operating independently, within a chain, or in a health system. Speakers at Asembia’s AXS26 Summit, in Las Vegas, stressed the importance of cybersecurity strategy.“As a pharmacist myself, I know how comple
  • Smart Pump–EHR Interoperability: Big Promise, Thin Evidence to Date

    Smart Pump–EHR Interoperability: Big Promise, Thin Evidence to Date
    By Marcus A. BanksConnecting smart infusion pumps directly to the electronic health record (EHR) has the potential to reduce medication errors, streamline nursing workflow, and improve charge capture, but the evidence supporting these gains is still immature, according to a recent systematic review (Intensive Crit Care Nurs 2026;97:104475).Interoperability allows a verified EHR order to auto-program the infusion pump and pump to auto-document the infusion back into the record, reducing manual ke
  • Building a CAR-T Bridge With Bispecifics for Lymphoma

    By Gina ShawBispecific antibodies (BiAbs) are achieving impressive results, in some cases more than doubling the survival gains seen with conventional chemotherapy. These advances are pushing oncology teams to reconsider whether these powerful anticancer drugs can be used earlier to carry more patients to potentially curative cellular therapy, speakers noted during a session at HOPA26, in New Orleans.Glofitamab-gxbm (Columvi, Genentech) is a case in point. When added to gemcitabine and oxaliplat
  • Ascension Error Exposes Gaps Hospitals Should Audit Now

    Ascension Error Exposes Gaps Hospitals Should Audit Now
    By Gina ShawPharmacy leaders should use the medication error that severely injured four joint replacement patients at Ascension Saint Thomas Hospital Midtown, in Nashville, Tennessee, as a prompt to examine their own sterile compounding safeguards—particularly barcode overrides, batch preparation, high-alert medication storage, technician competency assessment, and final pharmacist verification, medication safety experts said.The Tennessee Health Facilities Commission’s 80-page surve
  • SCCM Speakers: AI Tools Require Strong Governance and Rigorous Vetting

    Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksArtificial intelligence tools for clinical decision-making hold promise but may not be ready for everyday use, according to a discussion forum at the 2026 Critical Care Congress, in Chicago. Financial limitations may impede AI adoption as well.“The AI tools that are the most validated, as with sepsis detection, require institutional purchase before people can access them. Given financial constraint
  • SenderraRx Earns ACHC Reaccreditation in Specialty Pharmacy and Oncology Distinction

    Originally published by our sister publication Specialty Pharmacy ContinuumSenderra Specialty Pharmacy announced that it has earned reaccreditation in Specialty Pharmacy from the Accreditation Commission for Health Care (ACHC), including a Distinction in Oncology. Reaccreditation reflects an independent evaluation against nationally recognized standards for specialty pharmacy quality, safety, and patient care. The Oncology Distinction recognizes Senderra’s oncology-focused clinical oversig
  • Digital Supply Chain Pilot Targets Oncology Drug Shortages

    Digital Supply Chain Pilot Targets Oncology Drug Shortages
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina Shaw April GilesA first-of-its-kind supply chain transparency initiative has demonstrated that hospitals, distributors, and other stakeholders can share sensitive inventory data across organizational boundaries—and that doing so creates real planning value even when no drug shortage is underway.The Drug Resiliency & Transparency Pilot, led by the End Drug Shortages Alliance (EDSA), emerged from an August
  • Perioperative Apalutamide Improves Outcomes in High-Risk Localized Prostate Cancer

    Perioperative Apalutamide Improves Outcomes in High-Risk Localized Prostate Cancer
    Originally published by our sister publication Clinical Oncology NewsCHICAGO—Adding perioperative apalutamide (Erleada, Johnson & Johnson) to androgen deprivation therapy (ADT) delays the risk for metastasis or death and significantly improves pathologic response rates in patients with high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy, according to the phase 3 PROTEUS trial.Investigators said the results, which were presented at the 2026 American
  • FDA Finalizes Guidance to Broaden Cancer Trial Eligibility

    FDA Finalizes Guidance to Broaden Cancer Trial Eligibility
    By Jennifer KulpaThe FDA has finalized three guidance documents urging sponsors to ease overly restrictive eligibility criteria in cancer clinical trials. The recommendations address performance status, washout periods and concomitant medications, and laboratory values, potentially expanding enrollment to more patients treated in ambulatory settings.Issued in July 2026 by the FDA’s Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for Biologics Evaluation a
  • FDA Approves Hovilpri for Refractory HSV Lesions

    FDA Approves Hovilpri for Refractory HSV Lesions
    Originally published by our sister publication Infectious Disease Special EditionBy Meaghan Lee CallaghanThe FDA has approved pritelivir (Hovilpri, Asahi Kasei) for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, famciclovir, or valacyclovir in immunocompromised adults.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller;
  • The Backup for Drug Shortages Is Required by Law to Arrive Late

    The Backup for Drug Shortages Is Required by Law to Arrive Late
    figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Dalbir BainsAmerica's backup supply of sterile drugs is required by law to arrive late.Start with the scoreboard. ASHP counted
  • Medicaid Makes the Case for Food as Medicine

    Medicaid Makes the Case for Food as Medicine
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawMedically tailored meals delivered to high-risk Medicaid members were associated with 31% fewer hospitalizations, 20% fewer emergency department visits, and $3,433 lower total healthcare costs per person, in the largest real-world evaluation of the intervention to date.The cost reductions offset 98% of program costs, and among participants with cardiovascular disease, kidney disease, diabetes, depression, or h
  • Pestle and CriticalPoint Announce Partnership to Connect Compounding Education with Pharmacy Compliance Management

    Pestle, a pharmacy compliance and compounding workflow software, today announced a partnership with CriticalPoint by TRC Healthcare to connect compounding education with the training and compliance activities pharmacies manage in Pestle. Through the partnership, Pestle clients can purchase CriticalPoint education programs and access relevant courses directly from their Pestle training assignments.The partnership brings together CriticalPoint’s compounding education and Pestle’s tools
  • Solid Tumor Therapeutics: What’s New?

    Solid Tumor Therapeutics: What’s New?
    Originally published by our sister publication Specialty Pharmacy ContinuumHeather Ipema, PharmD, BCPSClinical Associate Professor, Drug Information SpecialistUniversity of Illinois Chicago Retzky College of PharmacySolid tumors are among the most common tumor types, comprising 8 of the top 10 most common cancers in men and women.1 Estimates for 2026 list lung cancer, colorectal cancer, and skin melanoma as the most likely new cancer diagnoses in men, and breast, lung, and colorectal as the most
  • Copay Programs, Coupons And Other Risky MC Maneuvers

    Copay Programs, Coupons And Other Risky MC Maneuvers
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawAs pharmacy benefit managers (PBMs) expand the use of copay accumulators, copay maximizers, alternative funding programs (AFPs), and prescription discount cards, specialty pharmacies are finding themselves caught in benefit designs that shift financial risk while obscuring who ultimately controls access to therapy.These programs are drawing heightened scrutiny as specialty drug spending continues to rise, manu
  • Combination bnAbs Sustained Viral Suppression in Children After ART Interruption

    Combination bnAbs Sustained Viral Suppression in Children After ART Interruption
    Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyCombination broadly neutralizing antibodies (bnAbs) maintained viral suppression for 24 weeks in the first children in Botswana with HIV to receive dual- or triple-bnAb treatment after scheduled antiretroviral (ART) therapy interruption, according to preliminary findings (abstract 152) presented at CROI 2026, in Denver.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em
  • Brief Caregiver Education Boosts TD Evaluation and Diagnosis

    Brief Caregiver Education Boosts TD Evaluation and Diagnosis
    Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawA single 10- to 15-minute online education
  • FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia

    FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia
    By PPN StaffThe FDA approved olanzapine as an extended-release injectable suspension (Weltruza, Teva) for the treatment of schizophrenia in adults.With the approval, the drug becomes the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of schizophrenia in adults. It does not require loading doses, oral supplementation, or post-injection monitoring.Extended-release injectable olanzapine “combines proven science and novel formulation
  • FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism

    FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism
    Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By PPN StaffThe FDA approved remibrutinib (Rhapsido, N
  • Registry Data Support Treating Mild Tardive Dyskinesia

    Registry Data Support Treating Mild Tardive Dyskinesia
    Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPatients whose tardive dyskinesia (TD) rate
  • Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment

    Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment
    figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPharmacists are well positioned to lead revenue cycle management for infused medications because they can follow a dru
  • In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s

    In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s
    figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawAfter Beth Israel Lahey Health (BILH) brought its employee prescription benefit in-house and began requiring employee
  • Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests

    Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests
    Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawNearly one-fourth of patients with tardive
  • FDA Approves Degevma, Biosimilar to Xgeva

    FDA Approves Degevma, Biosimilar to Xgeva
    Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved the biosimilar Degevma (denosumab-adet, Teva) for all indications of its reference product, Xgeva (denosumab, Amgen). These include:• preventing bone complications in adults with advanced cancer that has spread to the bone;• treating adults and skeletally mature adolescents with giant cell tumor of bone; and• treating hypercalcemia of malignancy.Degevma is Teva’s second bi
  • Financial Success Hinges on Proactive Enterprise Planning

    Financial Success Hinges on Proactive Enterprise Planning
    figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }McMahon Group.By Gina ShawHealth systems are looking to pharmacy to strengthen their finances, but many lack tools to track 340B performance or dedic
  • AAM Report: Generics and Biosimilars Saved $496 Billion in 2025

    AAM Report: Generics and Biosimilars Saved $496 Billion in 2025
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzGeneric and biosimilar drugs jointly created $496 billion in savings in 2025 for the U.S. healthcare system and for patients, according to a new report released by the Association for Accessible Medicines and the Biosimilars Council. Savings over the last decade were $3.5 trillion.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure im
  • Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy

    Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy
    Originally published by our sister publication Specialty Pharmacy ContinuumKristen Whelchel, PharmD, CSPProgram Director, Patient Care ImprovementBrooke Looney, PharmD, CSPClinical Specialty PharmacistStephanie White, PharmD, CSPClinical Specialty PharmacistAutumn D. Zuckerman, PharmD, BCPS, CSPDirector, Health Outcomes and ResearchVanderbilt Specialty PharmacyVanderbilt HealthNashville, TennesseeThe growing use of oral anticancer medications (OAMs) has enabled many patients to receive effective
  • Closing the Rx Gap Between Oncology Guidelines and Practice

    Closing the Rx Gap Between Oncology Guidelines and Practice
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksPersonalized oncology care depends on timely biomarker and genetic testing to guide treatment, but those tests are not always performed when patients need them, speakers said at Asembia’s AXS26 Summit, in Las Vegas. For specialty pharmacists, that gap represents both a patient-care challenge and a call to action: Help identify access barriers, reinforce appropriate testing and treatment pathways, a
  • The Ongoing Struggle of Sickle Cell Disease

    The Ongoing Struggle of Sickle Cell Disease
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumPatients with sickle cell disease (SCD) still face challenges with pain and fatigue as well as gaining access to a new gene therapy, according to two new studies.The first study found that acute pain and fatigue experienced by people with SCD are associated with higher costs and healthcare resource utilization—to the tune of an additional $7,689 higher per patient per year over counterparts who don&rsqu
  • AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models

    AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzThe American Hospital Association (AHA) submitted comments on Sept. 23 regarding the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act). The bill was introduced in July and, if passed, would make significant statutory changes to the 340B Drug Pricing Program.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-si
  • FDA Approves Juvmo for Parkinson’s Disease

    FDA Approves Juvmo for Parkinson’s Disease
    Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved tavapadon (Juvmo, AbbVie) tablets for adults with Parkinson’s disease. The drug is the first selective D1/D5 receptor agonist approved for the disease.The approval was based on data from the TEMPO-3 trial (ClinicalTrials.gov Identifer: NCT04542499) published in JAMA Neurology (2026;83;[5]:442-451).“Development of motor fluctuations is common in people with [Parkinson’s diseas
  • What You Should Know About This Hep C Pipeline Drug

    What You Should Know About This Hep C Pipeline Drug
    By Meaghan Lee CallaghanA new investigational drug for the treatment of hepatitis C could one day give clinicians an option that has fewer drug–drug interactions and only an eight-week treatment duration.Janet Hammond, MD, PhD, the chief development officer at Atea Pharmaceuticals, in Boston, sat down with Infectious Disease Special Edition to talk about their new drug in development, a combination of bemnifosbuvir and ruzasvir. Recent research presented at EASL 2026 (poster FRI-635)
  • FDA Approves Ustekinumab for Children With IBD

    FDA Approves Ustekinumab for Children With IBD
    Originally published by our sister publication Gastroenterology & Endoscopy NewsBy Katie PrinceThe FDA has approved ustekinumab (Stelara, Johnson & Johnson) for the treatment of children as young as 2 years of age with moderate to severe ulcerative colitis.Ustekinumab, which was approved to treat moderate to severe Crohn’s disease in this population in April, is the first biologic non–tumor necrosis factor inhibitor approved for pediatric patients with inflammatory bowel dise
  • Amneal Announces FDA Approval and Launch of Lanreotide Injection

    Amneal Pharmaceuticals, Inc. announced that the FDA has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA.“The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines business,” said Srinivas Kone, PhD, senior vice president and chief scientific o
  • Germfree Expands IV Pharmacy Capabilities through Certified Integration of Smarthood with Wolters Kluwer Simplifi+ IV Workflow

    Germfree Laboratories, LLC, a pioneering leader in modular and mobile cleanroom infrastructure, announced the certified integration of its Smarthood™ sterile compounding hood with Wolters Kluwer Health’s Simplifi+® IV Workflow Management with Assure-Trak® and Simplifi 797® solutions. The integration includes full hardware and software compatibility for highly accurate measurements with both volumetric and gravimetric workflows, allowing pharmacy teams to complete required
  • Genomic Test Identifies Breast Cancer Patients With Minimal Benefit From Chemotherapy

    Genomic Test Identifies Breast Cancer Patients With Minimal Benefit From Chemotherapy
    Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaUse of a 50-gene genomic test identified patients with high-clinical-risk, estrogen receptor–positive (ER+), HER2-negative early breast cancer who could safely avoid chemotherapy without increasing their risk for relapse or death, according to findings from the phase 3 OPTIMA trial.Trial DesignFor OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), the investigat
  • Selpercatinib Receives Traditional Approval for RET Fusion–Positive Solid Tumors

    Selpercatinib Receives Traditional Approval for RET Fusion–Positive Solid Tumors
    Originally published by our sister publication Clinical Oncology NewsBy Natasha Albaneze, MPHSelpercatinib (Retevmo, Lilly) was granted approval by the FDA to treat locally advanced or metastatic RET fusion–positive solid tumors in patients at least 2 years of age who have received prior systemic treatment.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:blo
  • New Teva Resource Aims to Move LAIs Earlier in Schizophrenia Care

    New Teva Resource Aims to Move LAIs Earlier in Schizophrenia Care
    Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }liaksandr Marko, alexkoral - stock.adobe.comBy Gina ShawTeva has launched
  • Specialty Pharmacy Teams Can Play Helpful Roles in Lupus Management

    Specialty Pharmacy Teams Can Play Helpful Roles in Lupus Management
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumSystemic lupus erythematosus (SLE), or lupus, is difficult to diagnose. Fortunately, specialty pharmacy teams can find updated treatment information through a guideline released in 2025 and help patients in multiple ways, an SLE expert noted during the National Association of Specialty Pharmacy’s inSPire2026 meeting, in National Harbor, Maryland.“The course of the disease is marked by flares and p
  • RFID Can Help Hospitals Control High-cost Medication Inventories

    RFID Can Help Hospitals Control High-cost Medication Inventories
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Robert HowardHospitals are under growing pressure to manage increasingly complex and costly medication inventories. Specialty drugs, biologics, and other high-value therapies represent a significant and expanding share of pharmacy budgets, yet many health systems still lack real-time visibility into where these medications are stored, how they are being used, and whether they are being protected from loss or waste. As

Follow @newsl_pharmacy on Twitter!